Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer’s Disease-Reference-Cited by-同舟云学术

Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer’s Disease

Published:2018-05-07 Issue:6 Volume:32 Page:579-591
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

del Cerro Patricia,Alquézar Carolina,Bartolomé Fernando,González-Naranjo Pedro,Pérez Concepción,Carro Eva,Páez Juan A.,Campillo Nuria E.,Martín-Requero Ángeles^ORCID

Funder

Secretaría de Estado de Investigación, Desarrollo e Innovación

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology

Link

http://link.springer.com/article/10.1007/s40263-018-0515-7/fulltext.html

Reference69 articles.

1. Hardy J, Bogdanovic N, Winblad B, Portelius E, Andreasen N, Cedazo-Minguez A, et al. Pathways to Alzheimer’s disease. J Intern Med. 2014;275(3):296–303.

2. Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71(4):505–8.

3. Finch CE, Morgan TE. Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr Alzheimer Res. 2007;4(2):185–9.